Fallopian Tube Cancer
Oncology·MeSH: Fallopian Tube Neoplasms
Prevalence
30.0 / 100K
3 drugs in development·2 companies·37 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| AZD5335 | ASTRAZENECA PLC (AZN) |
Phase 1(1)
| Drug | Company |
|---|---|
| imgn151 | ImmunoGen, Inc. (IMGN) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| Itraconazole | ASTRAZENECA PLC (AZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Fallopian Tube Cancer?
BioSniper tracks 3 drugs in development for Fallopian Tube Cancer across 2 companies.
How many clinical trials target Fallopian Tube Cancer?
There are 37 clinical trials targeting Fallopian Tube Cancer tracked by BioSniper.
What is the prevalence of Fallopian Tube Cancer?
The estimated prevalence of Fallopian Tube Cancer is approximately 30.0 per 100,000 population.
Deep-dive into Fallopian Tube Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis